GlassScriptPhysician profile
Pamela Tuli
NPI 1962684555
$27,159.25
in general payments reported to CMS, 2019-2025
90 companies · $4,351 in 2025
The $4,351 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,701 · 2020: $2,313 · 2021: $4,125 · 2022: $3,815 · 2023: $4,231 · 2024: $5,624 · 2025: $4,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,039.09 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,951.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,957.52 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,615.31 | 2019-2025 | Erleada, Akeega, Darzalex |
| Astrazeneca Pharmaceuticals LP | $1,318.36 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| Genentech USA, INC. | $1,307.62 | 2019-2025 | Venclexta, Phesgo, Columvi |
| E.R. Squibb & Sons, L.L.C. | $1,223.18 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $1,042.10 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $965.01 | 2019-2025 | |
| Amgen INC. | $905.03 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Pfizer INC. | $829.18 | 2019-2025 | |
| Daiichi Sankyo INC. | $821.02 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Lilly USA, LLC | $781.54 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $694.62 | 2019-2025 | Cabometyx |
| Gilead Sciences, INC. | $657.44 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $623.22 | 2019-2025 |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $565.77 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $373.21 | 2020-2025 | Iclusig, Ninlaro, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $362.48 | 2019-2025 | |
| Abbvie INC. | $341.49 | 2020-2025 | Venclexta |
| Puma Biotechnology, INC. | $334.45 | 2019-2025 | Nerlynx |
| Emd Serono, INC. | $330.71 | 2019-2024 | Bavencio |
| Beigene USA, INC. | $329.38 | 2020-2024 | Brukinsa |
| Adaptive Biotechnologies Corporation | $326.18 | 2023-2025 | Clonoseq |
| Seagen INC. | $322.98 | 2020-2023 | Adcetris, Tukysa |
| Stemline Therapeutics INC. | $320.77 | 2023-2025 | Orserdu |
| Tersera Therapeutics LLC | $306.02 | 2021-2025 | Zoladex, Xermelo |
| Pharmacyclics LLC, An Abbvie Company | $272.68 | 2020-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $263.38 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Pharmaessentia USA Corporation | $251.92 | 2023-2025 | Besremi |
| Glaxosmithkline, LLC. | $250.87 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Ipsen Biopharmaceuticals, INC | $233.59 | 2019-2024 | Onivyde, Somatuline Depot |
| Karyopharm Therapeutics INC. | $220.72 | 2020-2025 | Xpovio |
| Astellas Pharma US INC | $210.34 | 2021-2025 | Xospata, Padcev, Xtandi |
| Array Biopharma INC | $202.45 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Adc Therapeutics America, INC. | $177.85 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $142.20 | 2022-2024 | Libtayo |
| Sanofi-Aventis U.S. LLC | $124.19 | 2020-2022 | |
| Csl Behring | $121.51 | 2024 | Kcentra |
| Aveo Pharmaceuticals, INC. | $107.40 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $99.24 | 2024 | Provenge |
| Syndax Pharmaceuticals, INC. | $93.25 | 2025 | |
| Taiho Oncology, INC. | $92.56 | 2019-2025 | |
| Sobi, INC | $91.65 | 2022-2025 | |
| Clovis Oncology, INC. | $88.41 | 2019-2022 | |
| Beone Medicines USA, INC. | $86.20 | 2025 | Tevimbra, Brukinsa |
| Acceleron Pharma, INC. | $81.19 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.93 | 2024-2025 | Gilotrif |
| Lexicon Pharmaceuticals, INC. | $65.69 | 2020 | |
| Blueprint Medicines Corporation | $62.65 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $62.18 | 2020-2024 | Ultomiris |
| Kite Pharma, INC. | $59.98 | 2020-2024 | Yescarta |
| Emmaus Medical, INC. | $56.67 | 2023-2025 | Endari |
| Sun Pharmaceutical Industries INC. | $51.91 | 2023-2024 | Yonsa, Odomzo |
| Genmab U.S., INC. | $50.60 | 2024-2025 | Epkinly |
| Teva Pharmaceuticals USA, INC. | $48.69 | 2019 | |
| Mirati Therapeutics, INC. | $44.44 | 2023-2024 | Krazati |
| Recordati_rare_diseases_inc. | $43.30 | 2024-2025 | Enjaymo, Sylvant |
| Verastem, INC. | $40.89 | 2019 | |
| Servier Pharmaceuticals LLC | $38.70 | 2025 | |
| Morphosys, US INC. | $36.97 | 2023 | Monjuvi |
| Coherus Oncology, INC. | $34.34 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $31.60 | 2019 | |
| Kyowa Kirin, INC. | $28.83 | 2021 | |
| Boston Scientific Corporation | $28.72 | 2021 | |
| Tesaro, INC. | $28.67 | 2019 | |
| G1 Therapeutics, INC. | $28.64 | 2022 | |
| Dova Pharmaceuticals | $27.98 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $26.27 | 2025 | |
| Geron Corporation | $25.16 | 2025 | Rytelo |
| Novocure INC. | $24.07 | 2025 | Optune Lua (Novottf-200t) |
| Secura Bio, INC. | $23.84 | 2022 | |
| Spectrum Pharmaceuticals INC. | $21.66 | 2024 | Rolvedon |
| Springworks Therapeutics, INC. | $21.21 | 2025 | Ogsiveo |
| Foundation Medicine, INC. | $20.98 | 2023 | |
| Deciphera Pharmaceuticals INC. | $20.53 | 2024 | Qinlock |
| Tg Therapeutics, INC. | $19.31 | 2021 | |
| Apellis Pharmaceuticals, INC. | $18.70 | 2023 | Empaveli |
| Innate Pharma, INC | $17.88 | 2020 | |
| Cti Biopharma Corp. | $16.96 | 2022 | |
| Epizyme, INC. | $15.91 | 2022 | |
| Veracyte, INC. | $15.32 | 2023 | |
| Tactile Systems Technology INC | $15.14 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.33 | 2024 | Monoferric |
| Janssen Pharmaceuticals, INC | $14.03 | 2019 | |
| Myovant Sciences INC. | $13.93 | 2022 | |
| Medtronic, INC. | $13.02 | 2023 | Osteocool Rf Ablation System |
| Arbor Pharmaceuticals, INC. | $12.73 | 2021 | |
| Pharmaand Gmbh | $4.81 | 2025 | Rubraca |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Keytruda $928Opdivo $913Lenvima $436Lynparza $434Kisqali $389Verzenio $388Jaypirca $382Enhertu $368Scemblix $345Erleada $328Clonoseq $326Orserdu $321Venclexta $313Akeega $292Trodelvy $289Calquence $271Retevmo $254Besremi $252Cabometyx $236Darzalex $229Monjuvi $219Fabhalta $218Reblozyl $210Jakafi $209Imfinzi $207Tecvayli $205Pluvicto $181Padcev $180Talvey $176Bavencio $171Zoladex $170Phesgo $157Imbruvica $155Xpovio $147Xtandi $134Libtayo $130Adcetris $130Pemazyre $129Balversa $122Kcentra $122Tavalisse $121Rezlidhia $121Epkinly $121Promacta $117Iclusig $113Ninlaro $110Zejula $109Jemperli $109Piqray $109Rybrevant $108Columvi $108Tukysa $106Cablivi $106Mektovi $105Braftovi $105Polivy $105Stivarga $104Vitrakvi $104Provenge $99.24Lunsumio $97.94Elrexfio $94.64Brukinsa $91.75Xermelo $90.04Opdualag $89.45Tecentriq $88.83Welireg $85.67Sarclisa $84.49Lorbrena $79.10Nerlynx $78.45Doptelet $76.44Enjaymo $71.84Xospata $67.52Ibrance $64.62Fotivda $61.00Injectafer $60.76Tasigna $60.48Ojjaara $58.74Endari $56.67Itovebi $56.47Odomzo $51.91Yonsa $51.91Tevimbra $50.30Gavreto $49.48Xalkori $48.54Nubeqa $47.97Keytruda Qlex $47.22Mekinist $46.71Pomalyst $45.61Kyprolis $45.49Elahere $45.34Krazati $44.44Bosulif $43.43Datroway $42.94Lonsurf $42.56Inqovi $42.56Tibsovo $38.70Ayvakit $36.11Ultomiris $34.82Talzenna $34.65Lutathera $34.36
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Tuli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.